Seeking Alpha
29 May 2026, 23:24 UTC · 21w ago
Verdict
Headline leans bullish. We score MNKD +0.80 across one claim.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.80strongly bullish
What the story claims
1 claim · scored −1 bearish … +1 bullish
The FDA has approved Afrezza for the treatment of diabetes in pediatric patients aged 6 years and older.
More positive than 92% of claims this week
Which stocks this story touches
Continue reading
5 related stories
More positive than 88% of ticker scores this week
Scored by the NIS engine · methodology.
More positive than 88% of ticker scores this week
The company is discussing the FDA approval of its product Afrezza for a new pediatric patient population.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
9h ago
−7.2%
Price is moving against the score
$3.50 vs $3.77 close before publication (May 29) · not market-adjusted
MNKD chart →
